Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq 03:59:59 2024-02-27 pm EST 5-day change 1st Jan Change
430.9 USD -0.59% Intraday chart for Vertex Pharmaceuticals Incorporated +2.44% +5.91%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Vertex Pharmaceuticals Insider Sold Shares Worth $2,142,974, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $506,546, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,519,637, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Gets Positive Opinion for Kalydeco From European Medicines Agency to Treat Cystic Fibrosis MT
Vertex Pharmaceuticals Cystic Fibrosis Drug Gets Positive Opinion in EU For Treatment in Infants DJ
Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older CI
Prices for new US drugs rose 35% in 2023, more than the previous year RE
RBC Trims Price Target on Vertex Pharmaceuticals to $417 From $420, Keeps Sector Perform Rating MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,776,528, According to a Recent SEC Filing MT
Wolfe Research Initiates Vertex Pharmaceuticals With Outperform Rating, $515 Price Target MT
(OFFICIAL)-Latigo Biotherapeutics raises $135 mln for non-opioid painkillers RE
Vertex Pharmaceuticals Insider Sold Shares Worth $727,822, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,804,931, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $383,679, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,321,655, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $577,410, According to a Recent SEC Filing MT
European Commission Grants Crispr Therapeutics Conditional Marketing Permit for Casgevy MT
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY? (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia CI
Fed officials fail to convince investors, who are focused on earnings Our Logo
North American Morning Briefing : Stock Futures -2- DJ
ANALYST RECOMMENDATIONS : Caterpillar, Eli Lilly, Intel, Meta, T-Mobile... Our Logo
Stifel Adjusts Vertex Pharmaceuticals' Price Target to $430 From $373, Keeps Hold Rating MT
Leerink Partners Adjusts Vertex Pharmaceuticals' Price Target to $511 From $485, Keeps Outperform Rating MT
Goldman Sachs Adjusts Vertex Pharmaceuticals' Price Target to $578 From $559, Keeps Buy Rating MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $540 From $500, Maintains Overweight Rating MT
Chart Vertex Pharmaceuticals Incorporated
More charts
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (63.8%), Europe (30.3%) and other (5.9%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
433.5 USD
Average target price
460 USD
Spread / Average Target
+6.11%
Consensus
  1. Stock
  2. Equities
  3. Stock Vertex Pharmaceuticals Incorporated - Nasdaq
  4. News Vertex Pharmaceuticals Incorporated
  5. Vertex Pharmaceuticals' Kalydeco Secures Canadian Approval for Use in Younger Children
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW